Sign up
Pharma Capital

Dynavax shares set to rise on "encouraging' results of cancer drug

Biopharmaceutical company's treatment is aimed at head and neck cancers
Lab worker with microscope
The shares advanced in pre-market trading

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) are set to climb after the company reported its immune-oncology drug showed “promising” response rate in treating head and neck cancers.

The stock rose 14% to US$22.44 in pre-market trading.

Dynavax released data in an abstract at the American Association for Cancer research meeting.

The SD-101 drug “showed a promising 40%” overall response rate “indicative of potential activity in the difficult-to-treat setting of head and neck cancers,” MarketWatch reported, citing RBC Capital Markets analyst Brian Abrahams.

 

 

 



Register here to be notified of future DVAX Company articles
View full DVAX profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.